

Title (en)
METHODS FOR DETERMINING AND ACHIEVING THERAPEUTICALLY EFFECTIVE DOSES OF ANTI-CD47 AGENTS IN TREATMENT OF CANCER

Title (de)
VERFAHREN ZUR BESTIMMUNG UND ERZIELUNG THERAPEUTISCH WIRKSAMER DOSEN VON ANTI-CD47-MITTELN BEI DER BEHANDLUNG VON KREBS

Title (fr)
MÉTHODES DE DÉTERMINATION ET D'OBTENTION DE DOSES THÉRAPEUTIQUEMENT EFFICACES D'AGENTS ANTI-CD47 POUR LE TRAITEMENT DU CANCER

Publication
EP 3442578 B1 20220209 (EN)

Application
EP 17783254 A 20170414

Priority
• US 201662323330 P 20160415
• US 201662427679 P 20161129
• US 2017027662 W 20170414

Abstract (en)
[origin: WO2017181033A1] Methods are provided for treating a subject with an anti-CD47 agent.

IPC 8 full level
A61K 39/395 (2006.01); **A61P 35/00** (2006.01); **C07K 16/28** (2006.01)

CPC (source: CN EP KR US)
A61K 9/0019 (2013.01 - CN US); **A61P 35/00** (2018.01 - CN EP KR US); **C07K 16/2803** (2013.01 - CN EP KR US); **G01N 33/6854** (2013.01 - US); **A61K 2039/505** (2013.01 - CN EP KR US); **A61K 2039/545** (2013.01 - CN EP KR US); **C07K 2317/24** (2013.01 - EP KR US); **G01N 2333/70503** (2013.01 - US)

Citation (examination)
• JIE LIU ET AL: "Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential", PLOS ONE, vol. 10, no. 9, 21 September 2015 (2015-09-21), pages 1 - 23, XP055223677, DOI: 10.1371/journal.pone.0137345
• ROBERT UGER ET AL: "Blockade of the CD47-SIRP[alpha] axis: a promising approach for cancer immunotherapy", EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 20, no. 1, 5 November 2019 (2019-11-05), ASHLEY, LONDON; GB, pages 5 - 8, XP055731509, ISSN: 1471-2598, DOI: 10.1080/14712598.2020.1685976
• MORRISON CHRIS: "Industry shows increased appetite for macrophage biology", NATURE REVIEWS DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, vol. 19, no. 5, 17 April 2020 (2020-04-17), pages 295 - 297, XP037111810, ISSN: 1474-1776, [retrieved on 20200417], DOI: 10.1038/D41573-020-00075-3
• KAUR SUKHBIR ET AL: "Preclinical and clinical development of therapeutic antibodies targeting functions of CD47 in the tumor microenvironment", ANTIBODY THERAPEUTICS, vol. 3, no. 3, 25 July 2020 (2020-07-25), pages 179 - 192, XP055805185, DOI: 10.1093/abt/tbaa017

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2017181033 A1 20171019; AU 2017250809 A1 20181025; AU 2017250809 B2 20240229; AU 2024203396 A1 20240606; CA 3019676 A1 20171019; CN 109152837 A 20190104; CN 115350276 A 20221118; CN 117695387 A 20240315; EP 3442578 A1 20190220; EP 3442578 A4 20190410; EP 3442578 B1 20220209; EP 4074339 A1 20221019; EP 4349412 A2 20240410; EP 4349412 A3 20240612; ES 2909835 T3 20220510; JP 2019515899 A 20190613; JP 2022172278 A 20221115; JP 2024059764 A 20240501; JP 7442591 B2 20240304; JP 7532009 B2 20240813; KR 102505253 B1 20230302; KR 20180134367 A 20181218; KR 20230035435 A 20230313; KR 20240016445 A 20240206; PL 3442578 T3 20220620; PT 3442578 T 20220519; SI 3442578 T1 20220531; US 11472878 B2 20221018; US 11718670 B2 20230808; US 2019106491 A1 20190411; US 2023068235 A1 20230302; US 2023406923 A1 20231221

DOCDB simple family (application)
US 2017027662 W 20170414; AU 2017250809 A 20170414; AU 2024203396 A 20240522; CA 3019676 A 20170414; CN 201780029157 A 20170414; CN 202210926503 A 20170414; CN 202311544173 A 20170414; EP 17783254 A 20170414; EP 22155479 A 20170414; EP 24159469 A 20170414; ES 17783254 T 20170414; JP 2018553360 A 20170414; JP 2022140214 A 20220902; JP 2024023723 A 20240220; KR 20187032126 A 20170414; KR 20237006777 A 20170414; KR 20247002294 A 20170414; PL 17783254 T 20170414; PT 17783254 T 20170414; SI 201731120 T 20170414; US 201716089115 A 20170414; US 202217930621 A 20220908; US 202318210483 A 20230615